The link between PCSK9 inhibition and nonalcoholic fatty liver disease (NAFLD) offers intriguing insights into the broader implications of targeting PCSK9 in the context of cardiometabolic aging [16–23]. Here, PCSK9 is linked to metabolic dysfunction-associated steatotic liver disease.